Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Burt A. Adelman, insider at Verve Therapeutics

Burt A. Adelman Insider Information

Director of Verve Therapeutics
Burt Adelman is a thought leader and expert in drug development with more than 25 years of experience in the biotech industry. He was most recently executive vice president and chief medical officer at Dyax Corp., where he led the development of lanadelumab (Takhzyro), approved by the FDA and EMA for the prophylactic treatment of hereditary angioedema. Dyax was acquired by Shire in 2016. Dr. Adelman began his career at Biogen where he had an unparalleled track record, having led the successful development of important biologic therapeutics including Angiomax®, Avonex®, Amevive® and Tysabri®. At Biogen, he served in various roles including vice president of regulatory affairs, executive vice president of R&D, and executive vice president of portfolio strategy. Dr. Adelman is a member of the board of directors of Catabasis, Sirona, Clear Creek Bio, and Syntimmune, until it was sold to Alexion in 2018. He is also special advisor at Novo Ventures (US) Inc. He graduated from Cornell University Medical College, served as House Officer and Medical Resident at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) and Harvard Medical School, and completed his hematology fellowship at Brigham and Women’s Hospital (BWH). Dr. Adelman is a member of the Tufts Medical School Board of Overseers, an advisor to the Boston Biomedical Innovation Center at BWH, and a member of the investment committee of the Partners Innovation Fund (Mass General Hospital and BWH).

What is Burt A. Adelman's net worth?

The estimated net worth of Burt A. Adelman is at least $250,767.00 as of May 12th, 2022. Dr. Adelman owns 18,700 shares of Verve Therapeutics stock worth more than $250,767 as of May 22nd. This net worth estimate does not reflect any other assets that Dr. Adelman may own. Learn More about Burt A. Adelman's net worth.

How do I contact Burt A. Adelman?

The corporate mailing address for Dr. Adelman and other Verve Therapeutics executives is , , . Verve Therapeutics can also be reached via phone at 617-603-0070 and via email at [email protected] Learn More on Burt A. Adelman's contact information.

Has Burt A. Adelman been buying or selling shares of Verve Therapeutics?

During the last quarter, Burt A. Adelman has bought $121,500.00 in shares of Verve Therapeutics stock. 0 shares of BMO Capital Markets stock in a transaction that occurred on Sunday, May 22nd. Learn More on Burt A. Adelman's trading history.

Who are Verve Therapeutics' active insiders?

Verve Therapeutics' insider roster includes Burt Adelman (Director), Andrew Ashe (Insider), Andrew Bellinger (Insider), and Sekar Kathiresan (CEO). Learn More on Verve Therapeutics' active insiders.

Are insiders buying or selling shares of Verve Therapeutics?

In the last twelve months, Verve Therapeutics insiders bought shares 6 times. They purchased a total of 667,700 shares worth more than $12,737,718.00. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 283,151 shares worth more than $9,345,387.96. The most recent insider tranaction occured on May, 12th when Director Burt A Adelman bought 10,000 shares worth more than $121,500.00. Learn More about insider trades at Verve Therapeutics.

Information on this page was last updated on 5/12/2022.

Burt A. Adelman Insider Trading History at Verve Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy10,000$12.15$121,500.0018,700View SEC Filing Icon  
3/15/2022Buy4,000$21.38$85,520.00View SEC Filing Icon  
12/2/2021Buy4,700$31.34$147,298.00View SEC Filing Icon  
See Full Table

Burt A. Adelman Buying and Selling Activity at Verve Therapeutics

This chart shows Burt A Adelman's buying and selling at Verve Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verve Therapeutics Company Overview

Verve Therapeutics logo
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $13.41
Low: $12.59
High: $13.77

50 Day Range

MA: $18.51
Low: $11.64
High: $25.23

2 Week Range

Now: $13.41
Low: $11.30
High: $78.00


509,597 shs

Average Volume

657,526 shs

Market Capitalization

$652.53 million

P/E Ratio


Dividend Yield



How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.